Real world outcomes using PD-1 antibodies and BRAF+MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland

K Schumann, C Mauch, K C Klespe, C Loquai, U Nikfarjam, M Schlaak, L Akcetin, P Kölblinger, M Hoellwerth, M Meissner, G Mengi, A D Braun, M Mengoni, R Dummer, J Mangana, M A Sindrilaru, D Radmann, C Hafner, J Freund, K RappersbergerF Weihsengruber, F Meiss, L Reinhardt, F Meier, B Rainer, E Richtig, J M Ressler, C Höller, T Eigentler, T Amaral, W K Peitsch, U Hillen, W Harth, F Ziller, K Schatton, T Gambichler, L Susok, L V Maul, H Läubli, D Debus, C Weishaupt, S Börger, K Sievers, S Haferkamp, V Zenderowski, V A Nguyen, M Wanner, R Gutzmer, P Terheyden, K Kähler, S Emmert, A Thiem, M Sachse, S Gercken-Riedel, K M Kaune, K M Thoms, L Heinzerling, M V Heppt, S Tratzmiller, W Hoetzenecker, A Öllinger, A Steiner, T Peinhaupt, M Podda, S Schmid, U Wollina, T Biedermann, C Posch

Research output: Journal article (peer-reviewed)Journal article

10 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Real world outcomes using PD-1 antibodies and BRAF+MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science